Search research articles
Contact Us
Filters
Showing results (111-120 of 281) with videos related to
Page
of 29
Sort By:
Plos One
|
April 19, 2016
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
Sara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, et al.
Cell
|
April 17, 2026
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Jean-Christophe Marine, Osnat Bartok, Shira Sagie, et al.
Molecular Oncology
|
May 15, 2023
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages
Valentina Comunanza, Chiara Gigliotti, Simona Lamba, et al.
Cancers
|
March 10, 2022
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
Alessio Amatu, Gianluca Mauri, Federica Tosi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2003
PRL-3 expression in metastatic cancers
Alberto Bardelli, Saurabh Saha, Jason A Sager, et al.
Cancer Biology & Therapy
|
January 17, 2004
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells
Kurtis E Bachman, Brian G Blair, Keith Brenner, et al.
Plos One
|
September 1, 2009
Mutational profile of GNAQQ209 in human tumors
Simona Lamba, Lara Felicioni, Fiamma Buttitta, et al.
Cancer Treatment Reviews
|
October 22, 2020
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
Gianluca Mauri, Viviana Gori, Erica Bonazzina, et al.
Molecular Cancer Therapeutics
|
October 11, 2013
BRAF V600E is a determinant of sensitivity to proteasome inhibitors
Davide Zecchin, Valentina Boscaro, Enzo Medico, et al.
Page
of 29
Search research articles
Search
Showing results (111-120 of 281) with videos related to
Sort By:
Page
of 29
Plos One
|
April 19, 2016
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
Sara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 13, 2008
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
Federica Di Nicolantonio, Miriam Martini, Francesca Molinari, et al.
Cell
|
April 17, 2026
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Jean-Christophe Marine, Osnat Bartok, Shira Sagie, et al.
Molecular Oncology
|
May 15, 2023
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages
Valentina Comunanza, Chiara Gigliotti, Simona Lamba, et al.
Cancers
|
March 10, 2022
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
Alessio Amatu, Gianluca Mauri, Federica Tosi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2003
PRL-3 expression in metastatic cancers
Alberto Bardelli, Saurabh Saha, Jason A Sager, et al.
Cancer Biology & Therapy
|
January 17, 2004
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells
Kurtis E Bachman, Brian G Blair, Keith Brenner, et al.
Plos One
|
September 1, 2009
Mutational profile of GNAQQ209 in human tumors
Simona Lamba, Lara Felicioni, Fiamma Buttitta, et al.
Cancer Treatment Reviews
|
October 22, 2020
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
Gianluca Mauri, Viviana Gori, Erica Bonazzina, et al.
Molecular Cancer Therapeutics
|
October 11, 2013
BRAF V600E is a determinant of sensitivity to proteasome inhibitors
Davide Zecchin, Valentina Boscaro, Enzo Medico, et al.
Page
of 29